EpiStem

Sector:
Pharmaceuticals & Biotechnology
Exit:
Placement of blocks of shares on AIM

genedrive3

 Most Recent Exit  In Price/Share  Out Price/Share
 2014  £1.63  £3.20

EpiStem started as a revenue generating contract research company which channelled some of its revenues into developing its own proprietary research. The company is focused on developing therapies for epithelial diseases using adult stem cells including cancer, gastrointestinal diseases and skin damage. EpiStem’s contract research division services a number of big pharma groups including GlaxoSmithKline, Novartis and the US Department of Defense. One of EpiStem’s most successful products is its Genedrive diagnostic product, which is a handheld molecular (PCR) diagnostic instrument which generates results within 30 – 60 minutes, testing for diseases such as tuberculosis (TB).

Calculus Capital exited its investment in EpiStem by a series of coordinated placings in the market to meet institutional demand, with the last tranche successfully exited in 2014. EpiStem has now been renamed Genedrive Plc.